InVitria
PrivateLast Round
Grant
Oct 23, 2017
Total Funding Raised
$9.45M
Company Overview
InVitria operates in Healthcare & Life Sciences and is based in Junction City, Kansas. Its latest recorded funding round was a Grant round in October 2017.
InVitria is a biotechnology company that develops and manufactures recombinant, animal-origin-free proteins for biopharmaceutical manufacturing and formulation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
InVitria Comparables
Compare InVitria with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Levprot Bioscience | 71% | |
| Cape Bio Pharms | 69% | |
| Silvia Bio | 58% |
For institutional investors. Book with your work email.
InVitria Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 23, 2017 | ||||
| Grant | Jun 4, 2012 | ||||
| Convertible Debt | Jun 1, 2011 | ||||
| Grant | Aug 14, 2009 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
InVitria Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Allergy and Infectious Diseases | Grant |
| NIH RADx | Grant |
| Bill & Melinda Gates Foundation | Grant |
| Kansas Bioscience Authority | Convertible Debt, Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 5, 2026
Monthly visitors increased 65% MoM, reaching 5.7K.
- Jun 1, 2025
Monthly visitors increased 80% MoM, from 4.1K to 7.4K.
For institutional investors. Book with your work email.
InVitria Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about InVitria's valuation, stock price, and market status.
Is InVitria a public or private company?
InVitria is a private company.
What is the current stock price of InVitria?
InVitria is a private company, so its shares have no public market price. Caplight tracks InVitria's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is InVitria worth (valuation)?
Valuation information for InVitria is not publicly available.
Can I buy InVitria stock?
InVitria shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was InVitria's last funding round?
InVitria's most recent funding round was Grant on October 23, 2017.
Who are the main investors in InVitria?
Key investors in InVitria include National Institute of Allergy and Infectious Diseases, Bill & Melinda Gates Foundation, Kansas Bioscience Authority.
Will InVitria IPO soon?
No public IPO plans have been announced for InVitria.
How can I track InVitria secondary market activity?
Caplight tracks bids, offers, and trades in InVitria's shares on secondary markets.